References
- Den RB, George D, Pieczonka C, McNamara M. Ra-223 treatment for bone metastases in castrate-resistant prostate cancer: practical management issues for patient selection. Am J Clin Oncol 2019; 42: 399-406. doi: 10.1097/coc.0000000000000528
- De Vincentis G, Gerritsen W, Gschwend JE, Hacker M, Lewington V, O’Sullivan JM, et al. Advances in targeted alpha therapy for prostate cancer. Ann Oncol 2019; 0: 1-12. doi: 10.1093/annonc/mdz270
- Logothetis C, Morris MJ, Den R, Coleman RE. Current perspectives on bone metastases in castrate-resistant prostate cancer. Cancer Metastasis Rev 2018; 37: 189-96. doi: 10.1007/s10555-017-9719-4
- Bruland OS, Nilsson S, Fisher DR, Larsen RH. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res 2006; 12: 6250s-7s. doi: 10.1158/1078-0432.ccr-06-0841
- Henriksen G, Fisher DR, Roeske JC, Bruland OS, Larsen RH. Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice. J Nucl Med 2003; 44: 252-9. PMID: 12571218
- De Vincentis G, Follacchio GA, Frantellizzi V, Prelaj A, Farcomeni A, Giuli A, et al. 223Ra-dichloride therapy in an elderly bone metastatic castration-resistant prostate cancer patient: a case report presentation and comparison with existing literature. Aging Clin Exp Res 2017; 30: 677-80. doi: 10.1007/s40520-017-0826-4
- De Vincentis G, Monari F, Baldari S, Salgarello M, Frantellizzi V, Salvi E, et al. Narrative medicine in metastatic prostate cancer reveals ways to improve patient awareness & quality of care. Future Oncol 2018; 14: 2821-32. doi: 10.2217/fon-2018-0318
- De Vincentis G, Frantellizzi V, Follacchio GA, Farcomeni A, Pani A, Samaritani R,et al. No evidence of association between psychological distress and pain relief in patients with bone metastases from castration-resistant prostate cancer treated with 223Radium. Eur J Cancer Care 2019; 28: e13112. doi: 10.1111/ecc.13112
- Lecouvet FE, Talbot JN, Messiou C, Bourguet P, Liu Y, de Souza NM. Monitoring the response of bone metastases to treatment with Magnetic Resonance Imaging and nuclear medicine techniques: a review and position statement by the European Organisation for Research and Treatment of Cancer imaging group. Eur J Cancer 2014; 50: 2519-31. doi: 10.1016/j.ejca.2014.07.002
- Pyka T, Okamoto S, Dahlbender M, Tauber R, Retz M, Heck M, et al. Comparison of bone scintigraphy and (68)Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging 2016; 43: 2114-21. doi: 10.1007/s00259-016-3435-0
- Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148-59. doi: 10.1200/jco.2007.12.4487
- Dennis ER, Jia X, Mezheritskiy IS, Stephenson RD, Schoder H, Fox JJ, et al. Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer J Clin Oncol 2012; 30: 519-24. doi: 10.1200/jco.2011.36.5791
- Anand A, Morris MJ, Larson SM, Minarik D, Josefsson A, Helgstrand JT, et al. Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide. EJNMMI Res 2016; 6: 23. doi: 10.1186/s13550-016-0173-z
- Fosbol MO, Petersen PM, Kjaer A, Mortensen J. (223)Ra therapy of advanced metastatic castration-resistant prostate cancer: quantitative assessment of skeletal tumor burden for prognostication of clinical outcome and hematologic toxicity. J Nucl Med 2018; 59: 596-602. doi: 10.2967/jnumed.117.195677
- Uemura K, Miyoshi Y, Kawahara T, Yoneyama S, Hattori Y, Teranishi J, et al. Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer. BMC Cancer 2016; 16: 109. doi: 10.1186/s12885-016-2160-1
- Frantellizzi V, Farcomeni A, Follacchio GA, Pacilio M, Pellegrini R, Pani R, et al. A 3-variable prognostic score (3-PS) for overall survival prediction in metastatic castration-resistant prostate cancer treated with 223Radium-dichloride. Ann Nuc Med 2017; 32: 142-8. doi: 10.1007/s12149-017-1228-6
- Ricci M, Frantellizzi V, Bulzonetti N, De Vincentis G. Reversibility of castration resistance status after Radium-223 dichloride treatment: clinical evidence and review of the literature. Int J Radiat Biol 2019; 95: 554-61. doi: 10.1080/09553002.2019.1558301
- Baldari S, Boni G, Bortolus R, Caffo O, Conti G, De Vincentis G, et al. Management of metastatic castration-resistant prostate cancer: a focus on radium-223: opinions and suggestions from an expert multidisciplinary panel. Crit Rev Oncol Hematol 2017; 113: 43-51. doi: 10.1016/j.critrevonc.2017.03.001
- Van den Wyngaert T, Strobel K, Kampen WU, Kuwert T, van der Bruggen W, Mohan HK, et al. The EANM practice guidelines for bone scintigraphy. Eur J Nucl Med Mol Imaging 2016; 43: 1723-38. doi: 10.1007/s00259-016-3415-4
- Bradski G. The OpenCV Library. Dr Dobb’s Journal of Software Tools 2000; 120: 122-5. doi: citeulike-article-id:2236121
- Suzuki S. Topological structural analysis of digitized binary images by border following. Comput Vision, Graphics Image Process 1985; 30: 32-46. doi: 10.1016/0734-189X(85)90016-7
- Green G. An Essay on the application of mathematical analysis to the theories of electricity and magnetism. Journal fur die Reine und Angewandte Mathematik 1854; 1854: 161-221. doi: 10.1515/crll.1854.47.161
- Du Y, Carrio I, De Vincentis G, Fanti S, Ilhan H, Mommsen C, et al. Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer. Eur J Nuc Med Mol Imaging 2017; 44: 1671-8. doi: 10.1007/s00259-017-3756-7
- Osvaldo GF, Salvador MS, Zael SR, Nora SM. Radium-223 in metastatic hormone-sensitive high-grade prostate cancer: initial experience. Am J Nucl Med Mol Imaging 2017; 7: 236-45. PMID: 29181271
- Castello A, Macapinlac HA, Lopci E, Santos EB. Prostate-specific antigen flare induced by 223RaCl2 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 2018; 45: 2256-63. doi: 10.1007/ s00259-018-4051-y
- De Vincentis G, Follacchio GA, Frantellizzi V, Liberatore M, Monteleone F, Cortesi E. Prostate-Specific Antigen flare phenomenon during 223Radichloride treatment for bone metastatic Castration-Resistant Prostate Cancer: a case report. Clin Genitourin Cancer 2016; 14: e529-e533. doi: 10.1016/j.clgc.2016.04.014
- Sartor O, Coleman RE, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, et al. An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223. Ann Oncol 2017; 28: 1090-7. doi: 10.1093/annonc/mdx044
- Heinrich D, Bruland O, Guise TA, Suzuki H, Sartor O. Alkaline phosphatase in metastatic castration-resistant prostate cancer: reassessment of an older biomarker. Future Oncol 2018; 14: 2543-2556. doi: 10.2217/fon-2018-0087
- Gravis G, Boher J-M, Fizazi K, Joly F, Priou F, Marino P, et al. Prognostic factors for survival in noncastrate metastatic prostate cancer: validation of the glass model and development of a novel simplified prognostic model. Eur Urol 2015; 68: 196-204. doi: 10.1016/j.eururo.2014.09.022
- Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fosså SD, et al. Alpha emitter Radium-223 and survival in metastatic prostate cancer. N Eng J Med 2013; 369: 213-23. doi: 10.1056/nejmoa1213755
- Liu Y, Sheng J, Dong Z, Xu Y, Huang Q, Pan D, et al. The diagnostic performance of (18)F-fluoride PET/CT in bone metastases detection: a meta-analysis. Clin Radiol 2019; 74: 196-206. doi: 10.1016/j.crad.2018.12.011
- Sabbatini P, Larson SM, Kremer A, Zhang ZF, Sun M, Yeung H, et al. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol 1999; 17: 948-57. doi: 10.1200/JCO.1999.17.3.948
- Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS, et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019; 20: 408-419. doi: 10.1016/s1470-2045(18)30860-x
- O’Sullivan JM, Heinrich D, James ND, Nilsson S, Ost P, Parker CC, et al. The case against the European Medicines Agency’s change to the label for Radium-223 for the treatment of metastatic castration-resistant prostate cancer. Eur Urol 2018. 75: e51-2. doi: 10.1016/j.eururo.2018.11.003
- van der Doelen MJ, Mehra N, Hermsen R, Janssen MJR, Gerritsen WR, van Oort IM. Patient selection for Radium-223 therapy in patients with bone metastatic castration-resistant prostate cancer: new recommendations and future perspectives. Clin Genitourin Cancer 2019; 17: 79-87. doi: 10.1016/j.clgc.2018.11.008